Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Multicentre, Double-Blind, Randomized, Placebo-Controlled Study to Confirm the Safety and Efficacy of Subcutaneous Bioresorbable Afamelanotide Implants in Patients With Erythropoietic Protoporphyria (EPP)

NCT01605136 is registered in ClinicalTrials.gov with Clinuvel Pharmaceuticals Limited as lead sponsor.

NCT NCT01605136
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01605136 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Multicentre, Double-Blind, Randomized, Placebo-Controlled Study to Confirm the Safety and Efficacy of Subcutaneous Bioresorbable Afamelanotide Implants in Patients With Erythropoietic Protoporphyria (EPP)
Lead sponsor
Clinuvel Pharmaceuticals Limited
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2012
Completion date
July 31, 2013
Enrollment
93 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

erythropoietic protoporphyria